NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
Clinical Trials
3 trialsNCT00227760 2016-02-29
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00303862 2014-05-21
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated